IOL evolution for presbyopia

Article

“As we move into the 21st century the role of the IOL will evolve allowing better outcomes in cataract surgery and find new roles in surgery to improve vision such as through the treatment of presbyopia.”

“As we move into the 21st century the role of the IOL will evolve allowing better outcomes in cataract surgery and find new roles in surgery to improve vision such as through the treatment of presbyopia.” This was the view of Consultant Ophthalmic Surgeon, Queen's University Hospital, London, Mr. Charles Claoué on the news that the pioneering and sole British manufacturer of IOLs, Rayner Intraocular Lenses Ltd., has been awarded the prestigious Queen's Award for Enterprise.

“This recognition is well-deserved. Rayner is the most dynamic and innovative IOL company in the world and has a glorious history including having made the first ever IOL. At a time of global financial stress it is impressive for a British company to be achieving so much and excelling in the world marketplace.”

Rayner has advanced from making only monofocal lenses for cataract to excelling in toric and multifocal lens design. In the UK, premium multifocal IOLs treat presbyopia and are currently only available in private practice, for a cost of approximately £2,500 per eye, with no option to top-up from NHS–funded cataract surgery. Rayner's multifocal IOLs permit focus for long, intermediate and short distances. Patients report an average vision score of 92% following implantation of an IOL, where 100' would mean no disability. Rayner also remains committed to researching new biomaterials that offer exciting possibilities for future IOL development.

“We are a British manufacturer that is proud of the fact that we have refused to shift manufacture overseas but instead take our products to these markets and succeed. In Russia, Korea, Brazil, India, USA, Germany and many other countries we win by finding excellent local business partners, teaming up with their eye surgeon-customers and bringing internationally renowned surgeons from one country to another, passing on skills and exchanging clinical results. This week it is a tour of four Chinese cities where we are hosting educational seminars for audiences of hundreds of eye surgeons wanting to learn more about our lenses, especially the multifocal and multifocal toric lenses,” said Donald J. Munro, chairman and managing director of Rayner.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.